Clinical Trial

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Name: Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE) — clinical trial record (NCT06902844)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).

Trial Details

NCT Number	NCT06902844
Lead Sponsor	Tongji Hospital Collaborators: Nanjing IASO Biotechnology Co., Ltd.
Conditions	Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Enrollment	6 participants
Start Date	2025-04-05
Primary Completion	2027-10-31 (estimated)
Study Completion	2028-01-10 (estimated)
Updated on ClinicalTrials.gov	2025-03-30